K212121 is an FDA 510(k) clearance for the VHT-200 Wound Treatment System. Classified as Chamber, Oxygen, Topical, Extremity (product code KPJ), Class II - Special Controls.
Submitted by Vaporox, Inc. (Centennial, US). The FDA issued a Cleared decision on March 23, 2023 after a review of 624 days - an unusually long review period, suggesting complex equivalence evaluation.
This device falls under the General & Plastic Surgery FDA review panel, regulated under 21 CFR 878.5650 - the FDA general and plastic surgery device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind General & Plastic Surgery submissions.
View all Vaporox, Inc. devices